Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes
Uloženo v:
| Název: | Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes |
|---|---|
| Autoři: | Evans, Mark, Leelarathna, Lalantha, Sankalpa, Neupane, Gerry, Rayman, Sarah, Lumley, Iain, Cranston, Parth, Narendran, Katherine, Barnard-Kelly, Christopher, Sutton, Rachel, Elliott, Vicky, Taxiarchi, Georgios, Gkountouras, Matthew, Burns, Womba, Mubita, Naresh, Kanumilli, Maisie, Camm, Hood, Thabit, Emma, Wilmot |
| Přispěvatelé: | DSpace at Cambridge pro (8.1) |
| Zdroj: | FLASH-UK Trial Study Group 2022, 'Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes', The New England Journal of Medicine, vol. 387, no. 16, pp. 1477-1487. https://doi.org/10.1056/NEJMoa2205650 |
| Informace o vydavateli: | Massachusetts Medical Society, 2022. |
| Rok vydání: | 2022 |
| Témata: | Adult, Male, Blood Glucose, Glycated Hemoglobin, Blood Glucose Self-Monitoring, Type 1/blood, Diabetes Mellitus, Type 1/blood, Blood Glucose/analysis, Hypoglycemia/chemically induced, Middle Aged, Hypoglycemic Agents/administration & dosage, 16. Peace & justice, Hypoglycemia, 3. Good health, 03 medical and health sciences, Diabetes Mellitus, Type 1, 0302 clinical medicine, Diabetes Mellitus, Glycated Hemoglobin/analysis, Humans, Hypoglycemic Agents, Insulin, Female, Insulin/administration & dosage |
| Popis: | Background The benefits of intermittently-scanned continuous glucose monitoring with optional alarms (isCGM) for people with Type 1 diabetes (T1D) and high glycated hemoglobin levels are unknown. Methods In this multicenter, parallel-design, randomized controlled trial, 156 people with T1D and glycated hemoglobin values between 7.5% and 11.0% with mean (SD) age 43.5 (14.9) years, diabetes duration 21.1 (12.6) years, 44% women, were allocated (1:1) to isCGM (n=78) or self-monitoring of blood glucose with finger sticks (SMBG, n=78). The primary outcome was glycated hemoglobin at 24 weeks analyzed according to ‘intention to treat.’ Key secondary outcomes were sensor metrics, participant-reported outcome measures, and safety. Results The mean (SD) baseline glycated hemoglobin (%) was 8.7 (0.9) in the isCGM group and 8.5 (0.8) in the SMBG group, decreased to 7.9 (0.8) vs. 8.3 (0.9), respectively, at 24 weeks (adjusted mean difference -0.5, 95% confidence interval [CI] -0.7 to -0.3; p |
| Druh dokumentu: | Article |
| Popis souboru: | application/octet-stream |
| Jazyk: | English |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejmoa2205650 |
| DOI: | 10.17863/cam.90824 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/36198143 https://research.manchester.ac.uk/en/publications/6dd84428-6edd-4afc-a308-61d8ffbcce02 https://doi.org/10.1056/NEJMoa2205650 https://www.mendeley.com/catalogue/d4dbc73a-7d8c-3e91-a460-16e0f8c2f02c/ https://research.manchester.ac.uk/en/publications/6dd84428-6edd-4afc-a308-61d8ffbcce02 https://doi.org/10.1056/NEJMoa2205650 http://www.scopus.com/inward/record.url?scp=85140416626&partnerID=8YFLogxK |
| Rights: | CC BY ND URL: http://www.nejmgroup.org/legal/terms-of-use.htm |
| Přístupové číslo: | edsair.doi.dedup.....b3824fc4c289ce0a2b40ad38e131d1c3 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Background The benefits of intermittently-scanned continuous glucose monitoring with optional alarms (isCGM) for people with Type 1 diabetes (T1D) and high glycated hemoglobin levels are unknown. Methods In this multicenter, parallel-design, randomized controlled trial, 156 people with T1D and glycated hemoglobin values between 7.5% and 11.0% with mean (SD) age 43.5 (14.9) years, diabetes duration 21.1 (12.6) years, 44% women, were allocated (1:1) to isCGM (n=78) or self-monitoring of blood glucose with finger sticks (SMBG, n=78). The primary outcome was glycated hemoglobin at 24 weeks analyzed according to ‘intention to treat.’ Key secondary outcomes were sensor metrics, participant-reported outcome measures, and safety. Results The mean (SD) baseline glycated hemoglobin (%) was 8.7 (0.9) in the isCGM group and 8.5 (0.8) in the SMBG group, decreased to 7.9 (0.8) vs. 8.3 (0.9), respectively, at 24 weeks (adjusted mean difference -0.5, 95% confidence interval [CI] -0.7 to -0.3; p |
|---|---|
| ISSN: | 15334406 00284793 |
| DOI: | 10.1056/nejmoa2205650 |